Newly diagnosed HCC patients (n = 449) with serum GPC-3 > 150 pg/mL had lower overall survival (16; 95%CI: 13–24 months) than those with GPC-3 ≤ 150 pg/mL (36; 95%CI: 30–56 months, p < 0.001) [69]. Here, GPC3 is linked to hepatocellular carcinoma.